Srs Capital Advisors, Inc. Erasca, Inc. Transaction History
Srs Capital Advisors, Inc.
- $1.07 Billion
- Q3 2024
A detailed history of Srs Capital Advisors, Inc. transactions in Erasca, Inc. stock. As of the latest transaction made, Srs Capital Advisors, Inc. holds 846 shares of ERAS stock, worth $2,216. This represents 0.0% of its overall portfolio holdings.
Number of Shares
846
Previous 846
-0.0%
Holding current value
$2,216
Previous $1,000
100.0%
% of portfolio
0.0%
Previous 0.0%
Shares
1 transactions
Others Institutions Holding ERAS
# of Institutions
140Shares Held
229MCall Options Held
28.7KPut Options Held
117K-
Frazier Life Sciences Management, L.P. Menlo Park, CA19.4MShares$50.8 Million2.85% of portfolio
-
T. Rowe Price Investment Management, Inc. Baltimore, MD16.8MShares$44.1 Million0.03% of portfolio
-
Vr Adviser, LLC New York, NY16.2MShares$42.5 Million4.58% of portfolio
-
Suvretta Capital Management, LLC New York, NY13.8MShares$36.1 Million1.48% of portfolio
-
Vanguard Group Inc Valley Forge, PA13.3MShares$34.8 Million0.0% of portfolio
About Erasca, Inc.
- Ticker ERAS
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 122,147,000
- Market Cap $320M
- Description
- Erasca, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies for patients with RAS/MAPK pathway-driven cancers. The company's lead candidates include ERAS-007, an oral inhibitor of ERK1/2 for the treatment of non-small cell lung cancer, colorectal cancer, and acute myeloid leukemia; ...